#1 Clinical Trials Search in Europe

Desvenlafaxine Benzoate

This article discusses the use of Desvenlafaxine Benzoate in clinical trials for treating major depressive disorder. Desvenlafaxine Benzoate is being studied as part of an early intensified pharmacological treatment approach for patients who have experienced a first-time treatment failure with their initial medication. The trial aims to compare this new approach with standard treatment methods to determine its effectiveness in managing depression symptoms.

Table of Contents

What is Desvenlafaxine?

Desvenlafaxine Benzoate is a medication used in the treatment of major depressive disorder (MDD)[1]. It belongs to a class of drugs known as serotonin-norepinephrine reuptake inhibitors (SNRIs). These medications work by increasing the levels of two important neurotransmitters, serotonin and norepinephrine, in the brain, which can help improve mood and emotional well-being.

Medical Use

Desvenlafaxine is primarily used to treat major depressive disorder, a serious mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in daily activities[1]. It is often prescribed when other first-line treatments for depression have not been effective.

Administration

Desvenlafaxine is typically administered orally, meaning it is taken by mouth[1]. It comes in a tablet form, which makes it convenient for patients to take as prescribed by their healthcare provider.

Dosage

The dosage of Desvenlafaxine can vary depending on the individual patient’s needs and response to treatment. According to the clinical trial information, the maximum daily dose of Desvenlafaxine used in the study was 200 mg[1]. However, it’s important to note that your doctor will determine the appropriate dosage for you based on your specific condition and other factors.

Clinical Trial Information

Desvenlafaxine Benzoate is being studied as part of a clinical trial comparing different treatment approaches for major depressive disorder[1]. The trial is specifically looking at patients who have not responded well to their first treatment for depression. In this study, Desvenlafaxine is considered a “comparator” medication, which means it’s being used as a standard treatment to compare against other interventions.

Potential Benefits

While the specific outcomes of the trial are not yet known, the study aims to evaluate several potential benefits of treatment, including:

  • Reduction in depression symptoms[1]
  • Improvement in overall functioning and quality of life[1]
  • Reduction in anxiety symptoms[1]
  • Improvement in cognitive performance[1]

These potential benefits are being measured using various standardized scales and tests throughout the course of the study.

Considerations and Precautions

As with any medication, there are important considerations and precautions to keep in mind when taking Desvenlafaxine:

  • It should not be used by pregnant or breastfeeding women without consulting a doctor[1]
  • Patients with a history of substance use disorders should discuss this with their healthcare provider[1]
  • It may interact with other medications, so it’s important to inform your doctor about all medications you’re taking[1]
  • Regular check-ups and monitoring may be necessary to assess the medication’s effectiveness and any potential side effects[1]

It’s crucial to take Desvenlafaxine exactly as prescribed by your healthcare provider and to discuss any concerns or side effects you may experience.

Aspect Details
Study Drug Desvenlafaxine Benzoate
Condition Studied Major Depressive Disorder
Primary Objective Compare early intensified pharmacological treatment (EIPT) to treatment as usual (TAU) in patients with first-time treatment failure
Main Outcome Measure Change in Montgomery Åsberg Depression Rating Scale (MADRS) score
Treatment Duration 6 weeks
Maximum Daily Dose 200 mg
Administration Route Oral
Key Inclusion Criteria Age 18-65, diagnosed with major depressive disorder, first treatment failure
Key Exclusion Criteria Pregnancy, substance use disorder, previous ketamine use for depression

FAQ

  • What is Desvenlafaxine Benzoate? Desvenlafaxine Benzoate is a medication used to treat major depressive disorder. It belongs to a class of drugs called antidepressants and is being studied as part of an early intensified pharmacological treatment approach.
  • What is the main goal of the clinical trial involving Desvenlafaxine Benzoate? The main goal is to compare the effectiveness of an early intensified pharmacological treatment, which includes Desvenlafaxine Benzoate, with standard treatment for patients who have experienced a first-time treatment failure for major depressive disorder.
  • How is the effectiveness of the treatment measured? The effectiveness is primarily measured using the Montgomery Åsberg Depression Rating Scale (MADRS), which assesses changes in symptom severity from the beginning to the end of the six-week treatment period.
  • Who can participate in this clinical trial? Participants must be between 18 and 65 years old, diagnosed with major depressive disorder, and have experienced their first treatment failure on a first-line medication. They must also meet specific symptom severity criteria and experience functional impairment.
  • What are some of the exclusion criteria for the trial? Exclusion criteria include being pregnant or breastfeeding, having a current substance use disorder (except mild alcohol or cannabis use), having previously used ketamine or esketamine for depression, and having moderate to high suicidal ideation within the last two weeks.

Ongoing Clinical Trials on Desvenlafaxine Benzoate

  • Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

Glossary

  • Major Depressive Disorder: A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, which significantly impact daily life and functioning.
  • Montgomery Åsberg Depression Rating Scale (MADRS): A tool used by healthcare professionals to measure the severity of depressive episodes in patients with mood disorders.
  • Clinical Global Impression Scale (CGI): A rating system used in medical studies to evaluate the overall severity of a patient's condition and their improvement over time.
  • Early Intensified Pharmacological Treatment (EIPT): An approach that involves switching to a more potent medication regimen early in the treatment process when initial treatments have not been effective.
  • Treatment as Usual (TAU): The standard treatment approach typically used for a particular condition, serving as a comparison to new treatment methods in clinical trials.
  • Symptomatic Remission: A state where the symptoms of a disorder have significantly reduced or disappeared, often defined by specific score thresholds on rating scales.
  • Functional Impairment: Difficulties in performing daily activities or fulfilling roles due to physical or mental health issues.
  • Concomitant Medication: Additional medications taken by a patient alongside the primary treatment being studied in a clinical trial.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effect-of-ketamine-and-esketamine-in-patients-with-major-depressive-disorder-after-first-line-treatment-failure/